

Mometasone / Clotrimazole / Gentamicin Formulation

Date of last issue: 29.05.2024 Version Revision Date: SDS Number: 06.07.2024 6.0 412828-00024 Date of first issue: 14.12.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name Mometasone / Clotrimazole / Gentamicin Formulation

Other means of identification: **MOMETAMAX OINTMENT (52269)**

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-: Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company

20 Spartan Road

1619 Spartan, South Africa

Telephone +27119239300

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1A H360D: May damage the unborn child.

Short-term (acute) aguatic hazard, Cate-H400: Very toxic to aquatic life.

gory 1

Long-term (chronic) aquatic hazard, Cat-

H411: Toxic to aquatic life with long lasting effects.

egory 2

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word Danger



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Hazard statements : H360D May damage the unborn child.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Gentamicin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
clotrimazole	23593-75-1 245-764-8	Acute Tox. 4; H302 Acute Tox. 3; H311 Eye Irrit. 2; H319 Repr. 2; H361fd STOT RE 2; H373 (Liver, Kidney, Adrenal gland) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 ——— M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10	1
Gentamicin	1403-66-3 215-765-8	Repr. 1A; H360D STOT RE 1; H372	0,3



Mometasone / Clotrimazole / Gentamicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 29.05.2024
6.0	06.07.2024	412828-00024	Date of first issue: 14.12.2015

		(Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic	
Mometasone	83919-23-7	aquatic toxicity): 1 Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 100	0,1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.



Mometasone / Clotrimazole / Gentamicin Formulation

Date of last issue: 29.05.2024 Version Revision Date: SDS Number: 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks May damage the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage : Keep in properly labelled containers. Store locked up. Keep



Mometasone / Clotrimazole / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 29.05.2024

 6.0
 06.07.2024
 412828-00024
 Date of first issue: 14.12.2015

areas and containers tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
clotrimazole	23593-75-1	TWA	0.2 mg/m3 (OEB 2)	Internal
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB 2)	Internal
	Further information: OTO			
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 μg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : suspension
Colour : white to off-white

Odour : oily

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available Partition coefficient: n- : Not applicable

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) : No data available

Particle size : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method



Mometasone / Clotrimazole / Gentamicin Formulation

Version 6.0 Revision Date: 06.07.2024

SDS Number: 412828-00024

Date of last issue: 29.05.2024 Date of first issue: 14.12.2015

Components:

clotrimazole:

Acute oral toxicity : LD50 (Rat): 708 mg/kg

LD50 (Mouse): 761 mg/kg

LD50 (Rabbit): > 1.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,73 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Mouse): 923 mg/kg

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8.000 - 10.000 mg/kg

LD50 (Mouse): 10.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of:

administration)

LD50 (Rat): 67 - 96 mg/kg

Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg Application Route: Intravenous

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

LD50 (Mouse): > 2.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3,3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3,2 mg/l Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of :

administration)

LD50 (Rat): 300 mg/kg

Application Route: Subcutaneous Symptoms: Breathing difficulties



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Skin corrosion/irritation

Not classified based on available information.

Components:

clotrimazole:

Species : Rabbit

Result : No skin irritation

Gentamicin:

Species : Rabbit

Result : Mild skin irritation

Mometasone:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

clotrimazole:

Species : Rabbit

Result : Mild eye irritation

Gentamicin:

Species : Rabbit

Result : Mild eye irritation

Mometasone:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Gentamicin:

Remarks : No data available

Mometasone:



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitiser.

Germ cell mutagenicity

Not classified based on available information.

Components:

clotrimazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: in vitro micronucleus test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat

Application Route: Oral

Result: negative

Test Type: Mammalian spermatogonial chromosome aberra-

tion test (in vivo) Species: Hamster Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intravenous injection

Result: negative

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Result: negative

Test Type: Chromosomal aberration Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

clotrimazole:

Species : Rat
Application Route : Oral
Exposure time : 78 weeks
Result : negative

Gentamicin:

Carcinogenicity - Assess-

ment

: No data available

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

Reproductive toxicity

May damage the unborn child.

Components:

clotrimazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 50 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 50 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development

Species: Mouse Application Route: Oral

Developmental Toxicity: NOAEL: 200 mg/kg body weight

Result: No effects on foetal development

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 180 mg/kg body weight

Result: No effects on foetal development

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal experi-

ments.

Gentamicin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Fertility: NOAEL: 20 mg/kg body weight

Result: No significant adverse effects were reported



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: NOAEL: 3,6 mg/kg body weight

Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 75 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

Mometasone:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0,015 mg/kg body weight

Symptoms: Reduced embryonic survival, Reduced foetal

weight

Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0,06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-

tal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0,3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0,15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0,7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Mometasone:

Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure

Not classified based on available information.

Components:

clotrimazole:

Target Organs : Liver, Kidney, Adrenal gland

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Gentamicin:

Target Organs : Kidney, inner ear

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

clotrimazole:



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Species : Rabbit
LOAEL : 5 - 40 mg/kg
Application Route : Skin contact
Exposure time : 3 Weeks
Target Organs : Skin

Symptoms : Oedema, Fissuring, Necrosis, Redness

Species : Rat
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 18 Months

Target Organs : Liver, Kidney, Adrenal gland

Species : Dog LOAEL : 25 mg/kg Application Route : Oral

Exposure time : 6 - 12 Months Target Organs : Adrenal gland

Symptoms : Salivation, Lachrymation, Vomiting

Gentamicin:

Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney

Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks

Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks

Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat

NOAEL : 5 mg/kg

LOAEL : 10 mg/kg

Application Route : Intramuscular

Exposure time : 52 Weeks

Target Organs : Kidney, Blood

Species : Rat

NOAEL : 12,5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Mometasone:

Species : Rat

NOAEL : 0,005 mg/kg
LOAEL : 0,3 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0,5 mg/kg
Application Route : Oral
Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

NOAEL : 0,00013 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

Species : Dog NOAEL : 0,0005 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

Experience with human exposure

Components:

clotrimazole:

Skin contact : Symptoms: Rash, Itching, Blistering, Oedema, Redness Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

Gentamicin:

Ingestion : Target Organs: Kidney

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

deafness

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:

Remarks : Dermal absorption possible

SECTION 12: Ecological information

12.1 Toxicity

Components:

clotrimazole:

Toxicity to fish : LC50 (Brachydanio rerio (zebrafish)): > 0,29 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,02 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Desmodesmus subspicatus (green algae)): 0,268 mg/l

Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 0,017 mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox-

icity)

10

Toxicity to microorganisms : EC50 : > 10.000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,025 mg/l Exposure time: 32 d

Species: Oncorhynchus mykiss (rainbow trout)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,01 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

10

Gentamicin:



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 86 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 10 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1,5

μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4,7 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1,6 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

100

Toxicity to microorganisms : EC50 : 288,7 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

M-Factor (Chronic aquatic

toxicity)

1

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0,11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Toxicity to algae/aquatic

plants

: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3,2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms

EC50 : > 1.000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 1.000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,00014 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,34 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic

toxicity)

100

12.2 Persistence and degradability

Components:

clotrimazole:

Stability in water : Hydrolysis: 50 %(242 d)

Gentamicin:

Biodegradability : Result: rapidly degradable

Biodegradation: 100 % Exposure time: 28 d

Method: OECD Test Guideline 314

Mometasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:

Gentamicin:

Partition coefficient: n-

octanol/water

log Pow: < -2

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 107,1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4,68

12.4 Mobility in soil

Components:

Mometasone:

Distribution among environ-

mental compartments

log Koc: 4,02

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(clotrimazole, Gentamicin)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(clotrimazole, Gentamicin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(clotrimazole, Gentamicin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(clotrimazole, Gentamicin)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(clotrimazole, Gentamicin)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III Labels : 9

EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 964

aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 964

ger aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed.
H311 : Toxic in contact with skin.
H319 : Causes serious eye irritation.
H360D : May damage the unborn child.
H360Df : May damage the unborn child.

: May damage the unborn child. Suspected of damaging fertili-

ty.

H361fd : Suspected of damaging fertility. Suspected of damaging the

unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure if swallowed.

H373 : May cause damage to organs through prolonged or repeated

exposure if inhaled.

H373 : May cause damage to organs through prolonged or repeated

exposure if swallowed.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation;



Mometasone / Clotrimazole / Gentamicin Formulation

Version Revision Date: SDS Number: Date of last issue: 29.05.2024 6.0 06.07.2024 412828-00024 Date of first issue: 14.12.2015

tion (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States): UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Repr. 1A H360D Calculation method
Aquatic Acute 1 H400 Calculation method
Aquatic Chronic 2 H411 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.



Mometasone / Clotrimazole / Gentamicin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 29.05.2024

 6.0
 06.07.2024
 412828-00024
 Date of first issue: 14.12.2015

ZA / EN